Guizhou Xinbang Pharmaceutical Co., Ltd.

Shenzhen Stock Exchange 002390.SZ

Guizhou Xinbang Pharmaceutical Co., Ltd. EBIT for the year ending December 31, 2023: USD 58.68 M

Guizhou Xinbang Pharmaceutical Co., Ltd. EBIT is USD 58.68 M for the year ending December 31, 2023, a 19.38% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Guizhou Xinbang Pharmaceutical Co., Ltd. EBIT for the year ending December 31, 2022 was USD 49.15 M, a -36.66% change year over year.
Guizhou Xinbang Pharmaceutical Co., Ltd. EBIT for the year ending December 31, 2021 was USD 77.60 M, a 37.69% change year over year.
Guizhou Xinbang Pharmaceutical Co., Ltd. EBIT for the year ending December 31, 2020 was USD 56.36 M, a -14.68% change year over year.
Guizhou Xinbang Pharmaceutical Co., Ltd. EBIT for the year ending December 31, 2019 was USD 66.06 M, a 142.90% change year over year.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

Shenzhen Stock Exchange: 002390.SZ

Guizhou Xinbang Pharmaceutical Co., Ltd.

CEO	Ms. Lingzhong Kong
IPO Date	April 16, 2010
Location	China
Headquarters	Intersection of Hangtian Avenue and Xint
Employees	5,149
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Drugstores & Retail Pharmacies

Description

Guizhou Xinbang Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of Chinese herbal medicines and biological drugs in China and internationally. It offers cardiovascular and cerebrovascular, digestive system, endocrine, tumor and immune regulation, blood system, rheumatism and rheumatoid, urinary system, antipyretic analgesic, cold medication, gynecological treatment, and anti-infective drugs. The company was founded in 1995 and is headquartered in Guiyang, China.

Key trends

Past 5 years